Literature DB >> 27919999

Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder.

Lisa Manig1, Lukas Käsmann2, Stefan Janssen1,3, Dirk Rades1.   

Abstract

AIM: For patients with metastatic bladder cancer, radiotherapy is a good option to control symptoms and improve outcomes. Potential prognostic factors for survival including the radiation dose were investigated. PATIENTS AND METHODS: Ten factors were evaluated in 63 patients for association with survival after irradiation namely age, gender, performance status, initial T-category, initial N-category, metastases at initial diagnosis, number of metastases, metastatic sites, radiation dose and time from diagnosis of metastases to irradiation.
RESULTS: On univariate analysis, survival was negatively associated with Karnofsky performance score (KPS) ≤70 (p=0.033), initial N-category ≥1 (p=0.026) and radiation doses given as equivalent dose in 2-Gy fractions (EQD2) <20 Gy. Doses >30 Gy were slightly superior to 20-30 Gy. On multivariate analysis, EQD2 (p=0.015) maintained its significance; a trend was found for N-category (p=0.063) and KPS (p=0.073).
CONCLUSION: Predictors for survival after irradiation of metastases from bladder cancer were identified. Radiation doses ≥20 Gy should be used. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Bladder cancer; irradiation; metastases; predictive factors; radiation dose

Mesh:

Year:  2016        PMID: 27919999     DOI: 10.21873/anticanres.11275

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Factors Impacting the Overall Survival of Patients Irradiated for Invasive Carcinoma of the Urinary Bladder.

Authors:  Dirk Rades; Lisa Manig; Stefan Janssen; Steven E Schild
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

2.  A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer.

Authors:  Lisa Manig; Stefan Janssen; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

3.  Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder.

Authors:  Karel Decaestecker; Valérie Fonteyne; Willem Oosterlinck
Journal:  Transl Androl Urol       Date:  2017-12

4.  Histologically confirmed distant metastatic urothelial carcinoma from the urinary bladder: a retrospective review of one institution's 20-year experience.

Authors:  Youngeun Yoo; Junghye Lee; Heae Surng Park; Min-Sun Cho; Sun Hee Sung; Sanghui Park; Euno Choi
Journal:  J Pathol Transl Med       Date:  2020-12-03

5.  The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy.

Authors:  Husam A Alqaisi; Carlos Stecca; Zachary W Veitch; Jamila Riromar; Jeenan Kaiser; Nazanin Fallah-Rad; Di Maria Jiang; Scott North; Sunil Samnani; Nimira Alimohamed; Srikala S Sridhar
Journal:  Ther Adv Med Oncol       Date:  2022-05-01       Impact factor: 5.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.